Regulatory approval

Published by the Health Canada. Approved

LORBRENA (lorlatinib) is indicated as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).

This is written in the approval document.

Citation

Pfizer Canada ULC. Lorbrena (lorlatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00083472.PDF. Revised February 2026. Accessed April 2026.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals